Codexis Inc., of Redwood City, Calif., said it signed a platform technology license agreement with Glaxosmithkline plc, of London, in which Codexis grants a license to its Codeevolver protein engineering platform technology in the field of human health care. The license allows GSK to use Codexis' technology to develop enzymes for use in the manufacture of GSK's pharmaceutical and health care products, and GSK also may use the technology to develop new therapeutic, diagnostic and prophylactive products in the human health field. Under the terms, Codexis is eligible to receive up to $25 million over about the next two years, $6 million of which will be paid up front and $19 million upon satisfactory completion of technology transfer milestones. Codexis also has the potential to receive numerous additional milestone payments, ranging from $5.75 million to $38.5 million per project, based on GSK's successful application of the licensed technology. In addition, Codexis could get royalties on net sales of a limited set of products developed by GSK using Codexis' protein engineering platform. Shares of Codexis (NASDAQ:CDXS) gained 62 cents, or 44 percent, to close Tuesday at $2.03.